Roche has released its full-year 2025 financial results, reporting group revenue of CHF 61.5 billion (USD 74.4 billion), representing a 7% increase at constant exchange rates. The company's pharmaceutical division generated revenue of CHF 47.7 billion (USD 57.7 billion), a 9% year-on-year growth, driven by strong performances in oncology, haematology, neurology, immunology and ophthalmology. Key growth drivers included Xolair, Phesgo and Polivy, each posting growth exceeding 30%. Roche invested CHF 12.2 billion (USD 14.8 billion) in R&D, accounting for roughly 20% of total revenue.

In China, Roche's pharmaceutical revenue grew 10% to CHF 3.0 billion (USD 3.7 billion), though its diagnostics business in the region declined by 24%. The company also provided an update on its pipeline, adding 10 new projects and removing seven in the fourth quarter. Notable additions include a B7H3 ADC licensed from MediLink Therapeutics, the initiation of a Phase III trial for a KRAS G12C inhibitor combined with pembrolizumab, and the submission of a new drug application for the oral selective estrogen receptor degrader (SERD) giredestrant. Roche forecasts mid-single-digit sales growth for the group in 2026.

According to PharmCube's NextBiopharm® database, Roche boasts 181 products in its portfolio and over 300 projects under development. Click here to request a free trial for NextBiopharm®.